These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9067471)

  • 21. The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease.
    Kraszpulski M; Soininen H; Helisalmi S; Alafuzoff I
    Acta Neurol Scand; 2001 Feb; 103(2):88-92. PubMed ID: 11227137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.
    Lehtovirta M; Soininen H; Helisalmi S; Mannermaa A; Helkala EL; Hartikainen P; Hänninen T; Ryynänen M; Riekkinen PJ
    Neurology; 1996 Feb; 46(2):413-9. PubMed ID: 8614504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high incidence of apolipoprotein E epsilon4 allele in middle-aged non-demented subjects with cerebral amyloid beta protein deposits.
    Arai T; Ikeda K; Akiyama H; Haga C; Usami M; Sahara N; Iritani S; Mori H
    Acta Neuropathol; 1999 Jan; 97(1):82-4. PubMed ID: 9930898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.
    Tiraboschi P; Hansen LA; Masliah E; Alford M; Thal LJ; Corey-Bloom J
    Neurology; 2004 Jun; 62(11):1977-83. PubMed ID: 15184600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.
    Juottonen K; Lehtovirta M; Helisalmi S; Riekkinen PJ; Soininen H
    J Neurol Neurosurg Psychiatry; 1998 Sep; 65(3):322-7. PubMed ID: 9728943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease.
    Nyarko JNK; Quartey MO; Pennington PR; Heistad RM; Dea D; Poirier J; Baker GB; Mousseau DD
    Neuroscience; 2018 Mar; 373():20-36. PubMed ID: 29331531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence.
    Jelic V; Julin P; Shigeta M; Nordberg A; Lannfelt L; Winblad B; Wahlund LO
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):59-65. PubMed ID: 9221969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease.
    Corey-Bloom J; Tiraboschi P; Hansen LA; Alford M; Schoos B; Sabbagh MN; Masliah E; Thal LJ
    Neurology; 2000 Jan; 54(2):403-6. PubMed ID: 10668702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Apolipoprotein E4 and late-onset Alzheimer's disease].
    Tamaoka A
    Nihon Rinsho; 1994 Dec; 52(12):3257-65. PubMed ID: 7853720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.
    Mann DM; Pickering-Brown SM; Takeuchi A; Iwatsubo T;
    Am J Pathol; 2001 Jun; 158(6):2165-75. PubMed ID: 11395394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.
    Prince JA; Zetterberg H; Andreasen N; Marcusson J; Blennow K
    Neurology; 2004 Jun; 62(11):2116-8. PubMed ID: 15184629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease.
    Lucotte G; Aouizérate A; Gérard N; Turpin JC; Landais P
    Am J Med Genet; 1995 Dec; 60(6):566-9. PubMed ID: 8825898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease.
    Whitwell JL; Tosakulwong N; Weigand SD; Graff-Radford J; Ertekin-Taner N; Machulda MM; Duffy JR; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Josephs KA;
    Neurobiol Aging; 2021 Dec; 108():90-98. PubMed ID: 34551374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.
    Beffert U; Cohn JS; Petit-Turcotte C; Tremblay M; Aumont N; Ramassamy C; Davignon J; Poirier J
    Brain Res; 1999 Oct; 843(1-2):87-94. PubMed ID: 10528114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease.
    McNamara MJ; Gomez-Isla T; Hyman BT
    Arch Neurol; 1998 Jul; 55(7):1001-4. PubMed ID: 9678319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein E polymorphism and Alzheimer's disease.
    Poirier J; Davignon J; Bouthillier D; Kogan S; Bertrand P; Gauthier S
    Lancet; 1993 Sep; 342(8873):697-9. PubMed ID: 8103819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients.
    Marra C; Bizzarro A; Daniele A; De Luca L; Ferraccioli M; Valenza A; Brahe C; Tiziano FD; Gainotti G; Masullo C
    Dement Geriatr Cogn Disord; 2004; 18(2):125-31. PubMed ID: 15211066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease.
    Lendon CL; Thaker U; Harris JM; McDonagh AM; Lambert JC; Chartier-Harlin MC; Iwatsubo T; Pickering-Brown SM; Mann DM
    Neurosci Lett; 2002 Aug; 328(3):314-8. PubMed ID: 12147333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.